Persomics AB’s core patents granted in all territories filed

Share Article

Persomics AB completes impressive portfolio of key patents in miniaturization technology for phenotypic screening, research biology and drug discovery.

We have the ability to produce dramatically smaller arrays with high speed and precision

Over the past year Persomics AB has made major strides in strengthening its IP portfolio, based on the R&D it has licensed from the CSIR (South Africa). Grant has been obtained for its full set of key patents in all territories filed. This includes two patent families in the United States, Europe and Korea, a patent in South Africa and an additional patent in the USA.

“With the recent grant of our second core patent at the European Patent Office, we have now completed our core IP portfolio and have protection for all key aspects of our ground-breaking miniaturization technology,” said Dr. Sean Moolman, IP Manager at Persomics.

“Our ability to produce dramatically smaller arrays with high speed and precision means that we can slash the cost, accelerate the speed and increase the scale of functional genomics and phenotypic discovery screening efforts.”

“The speed with which the core patents have been granted in key examining territories is an indication of the potential of the technology and strength of the intellectual property strategy we have pursued,” said Dr. Neil Emans (CEO, Persomics USA Inc.).

Patents have been granted covering the printing methodology for Persomics AB’s paradigm-shifting array plates, as well as related supporting reverse transfection methodologies and layered arrays.

In addition, Persomics AB has secured an exclusive license to the seminal reverse transfection patents of Sabatini (US 6,544,790 & US 6,951,757).

Please send enquiries to:
Sean Moolman, Ph.D.
IP Manager

About Persomics
Persomics provides ImagineArraysTM, a technology that miniaturizes, accelerates and increases the scale of phenotypic screening. Researchers investigating the function of the human genome and disease are no longer limited by automation requirements or cost, but by their need to discover more. With Persomics this can be achieved at a fraction of the investment required in large industrial research labs. With our technology the science can go further, faster.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Neil Emans
Persomics
+1 (617) 467-8896
Email >

Sean Moolman
Visit website